- Home
- REGN vs TFC Comparison
REGN vs TFC Comparison
Compare REGN & TFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | REGN | TFC |
|---|---|---|
| Founded | 1988 | 1872 |
| Country | United States | United States |
| Employees | N/A | 38711 |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.6B | 60.4B |
| IPO Year | 1995 | N/A |
Fundamental Metrics
Financial Performance| Metric | REGN | TFC |
|---|---|---|
| Price | $648.67 | $51.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 25 | 14 |
| Target Price | ★ $830.16 | $54.11 |
| AVG Volume (30 Days) | 986.6K | ★ 10.2M |
| Earning Date | 04-29-2026 | 04-17-2026 |
| Dividend Yield | 0.55% | ★ 4.11% |
| EPS Growth | ★ 8.19 | N/A |
| EPS | ★ 6.75 | N/A |
| Revenue | ★ $5,872,227,000.00 | N/A |
| Revenue This Year | $12.45 | $17.27 |
| Revenue Next Year | $10.13 | $4.48 |
| P/E Ratio | $96.34 | ★ $13.80 |
| Revenue Growth | ★ 20.82 | N/A |
| 52 Week Low | $541.00 | $40.79 |
| 52 Week High | $821.11 | $56.20 |
Technical Indicators
Market Signals| Indicator | REGN | TFC |
|---|---|---|
| Relative Strength Index (RSI) | 57.26 | 60.72 |
| Support Level | $593.21 | $48.26 |
| Resistance Level | $664.00 | $51.45 |
| Average True Range (ATR) | 14.91 | 1.27 |
| MACD | 6.95 | 0.18 |
| Stochastic Oscillator | 86.77 | 84.76 |
Price Performance
Historical ComparisonAbout REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
About TFC Truist Financial Corporation
Truist Financial is one of the three super-regional banks in the US, with around $550 billion in assets as of the first quarter of 2026. Truist emerged from the combination of BB&T and SunTrust in 2019. Based in Charlotte, North Carolina, the bank's footprint is largely in the Mid-Atlantic and Southeast. Apart from retail and commercial banking operations, the bank also offers online and point-of-sale consumer lending, cards, wealth management, investment banking, and other banking services.